CN115171918A - Method, device and equipment for monitoring clinical application of antibacterial drugs - Google Patents
Method, device and equipment for monitoring clinical application of antibacterial drugs Download PDFInfo
- Publication number
- CN115171918A CN115171918A CN202210806466.5A CN202210806466A CN115171918A CN 115171918 A CN115171918 A CN 115171918A CN 202210806466 A CN202210806466 A CN 202210806466A CN 115171918 A CN115171918 A CN 115171918A
- Authority
- CN
- China
- Prior art keywords
- index
- monitoring
- early warning
- value corresponding
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The application provides an antibacterial drug clinical application monitoring method, device and equipment, and belongs to the technical field of drug monitoring and early warning. The method comprises the steps of acquiring clinical use data of the antibacterial drugs to be monitored in a preset hospital within a preset monitoring period; calculating the parameter value of the use index of the antibacterial drug to be monitored in a preset monitoring period according to clinical use data; calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index; and carrying out early warning monitoring on the use indexes of the antibacterial drugs to be monitored according to the monitoring index values corresponding to the use indexes. Therefore, accurate monitoring index values can be adopted in different monitoring periods, the using condition of the antibacterial drugs can be monitored and early warned in time, and the hospital can manage the antibacterial drugs conveniently.
Description
Technical Field
The invention relates to the technical field of drug monitoring and early warning, in particular to a method, a device and equipment for monitoring clinical application of an antibacterial drug.
Background
The antibacterial drug has wide clinical application, and is mainly used for killing bacteria and resisting infection. With the wide clinical use of drugs, due to the influence of various factors, drug abuse and unreasonable conditions of the drugs are continuously enhanced, so that the drug resistance of most pathogenic bacteria is increased, the treatment effect of patients is influenced, the drug-induced diseases are caused, medical resources are wasted, and the strengthening of the control of antibacterial drugs is very important at present.
Health committee has developed a plurality of policies about the clinical application management of antibacterial drugs, and makes specific provisions on evaluation indexes such as antibacterial drug utilization rate, inpatient antibacterial drug use strength, inpatient antibacterial drug use pre-rate and the like. Weijian committee developed national antimicrobial clinical application monitoring network, adopted retrospective random sampling survey mode to make statistical analysis on monitoring data, registered hospitals accessing network reported directly through network, and reported data according to month, quarter and year. An antibacterial drug clinical application monitoring system is not established in a hospital, the hospital needs to manually finish combing, extracting, counting and reporting of clinical drug application monitoring data, the workload is high, and errors are easy to occur; the clinical application condition of the antibacterial agent in the hospital can not be dynamically monitored, doctors cannot see the clinical application condition of the antibacterial agent in real time, and early warning cannot be timely sent to managers.
Disclosure of Invention
The invention aims to provide an antibacterial clinical application monitoring method, device and equipment aiming at the defects in the prior art, so as to solve the problems that the clinical application condition of the antibacterial in a hospital can not be dynamically monitored, an antibacterial manager can be timely warned and the like in the prior art.
In order to achieve the above purpose, the technical solutions adopted in the embodiments of the present application are as follows:
in a first aspect, the embodiments of the present application provide a method for monitoring clinical application of an antibacterial agent, the method including:
acquiring clinical use data of an antibacterial drug to be monitored in a preset hospital within a preset monitoring period;
calculating the parameter value of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical use data;
calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and a parameter threshold value corresponding to the use index;
and carrying out early warning monitoring on the use index of the antibacterial drug to be monitored according to the monitoring index value corresponding to the use index.
Optionally, the calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold corresponding to the use index includes:
and calculating a monitoring index value corresponding to the use index according to the ratio of the parameter value of the use index to the parameter threshold value corresponding to the use index.
Optionally, the performing, according to the monitoring index value corresponding to the use index, early warning and monitoring of the use index on the antibacterial drug to be monitored includes:
determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: and the early warning level corresponds to the early warning index range.
Optionally, the usage index includes: a first usage index;
and determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: the early warning level corresponding to the early warning index range comprises the following steps:
if the monitoring index value corresponding to the first use index is greater than or equal to a first early warning threshold value and less than 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level; the first early warning threshold value is any value which is greater than 0 and less than 1;
if the monitoring index value corresponding to the first use index is greater than or equal to 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level;
wherein the first warning level is lower than the second warning level.
Optionally, the usage indicator comprises: a second usage index;
and determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: the early warning level corresponding to the early warning index range comprises the following steps:
if the monitoring index value corresponding to the second use index is greater than or equal to 1 and smaller than a second early warning threshold value, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level; the second early warning threshold value is any value larger than 1;
if the monitoring index value corresponding to the second use index is smaller than 1, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level;
wherein the first warning level is lower than the second warning level.
Optionally, the calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold corresponding to the use index includes:
calculating the variable quantity of the use parameter corresponding to the use index according to the parameter value of the use index and the historical parameter value corresponding to the use index in the historical monitoring period before the preset monitoring period;
and calculating a monitoring index value corresponding to the use index according to the ratio of the variable quantity of the use parameter corresponding to the use index to the parameter value of the use index.
Optionally, if the clinical usage data comprises: clinical usage data of at least one monitoring group; the calculating the parameter value of the usage index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical usage data comprises the following steps:
calculating a parameter value of the usage index within each monitoring group according to clinical usage data of the monitoring group;
the calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index includes:
and calculating the monitoring index value of the use index in each monitoring group according to the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group.
Optionally, the at least one monitoring packet comprises: at least one monitoring group of a drug code group, a drug category group, a department group, a doctor group, an administration route group, and a hospital occurrence group.
In a second aspect, embodiments of the present application provide an antimicrobial clinical application monitoring device, including:
the acquisition module is used for acquiring clinical use data of the antibacterial drugs to be monitored in a preset hospital within a preset monitoring period;
the first calculation module is used for calculating a parameter value of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical use data;
the second calculation module is used for calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index;
and the early warning module is used for carrying out early warning monitoring on the use index on the antibacterial medicament to be monitored according to the monitoring index value corresponding to the use index.
In a third aspect, an embodiment of the present application provides an electronic device, including: the processor and the storage medium are connected in a communication manner through a bus, the storage medium stores program instructions executable by the processor, and the processor calls a program stored in the storage medium to execute the steps of the method for monitoring clinical application of antibacterial drugs according to any one of the first aspect.
Compared with the prior art, the method has the following beneficial effects:
the application provides an antibacterial drug clinical application monitoring method, device and equipment, wherein the method comprises the steps of acquiring clinical use data of an antibacterial drug to be monitored in a preset monitoring period in a preset hospital; calculating the parameter value of the use index of the antibacterial drug to be monitored in a preset monitoring period according to clinical use data; calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index; and carrying out early warning monitoring on the use indexes of the antibacterial drugs to be monitored according to the monitoring index values corresponding to the use indexes. Therefore, accurate monitoring index values can be adopted in different monitoring periods, the using condition of the antibacterial drugs can be monitored and early warned in time, and the hospital can manage the antibacterial drugs conveniently.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and those skilled in the art can also obtain other related drawings based on the drawings without inventive efforts.
Fig. 1 is a schematic flow chart of a method for monitoring clinical application of an antibacterial agent according to an embodiment of the present application;
fig. 2 is a schematic flowchart of a monitoring and early warning method based on a first usage index according to this embodiment;
fig. 3 is a schematic flow chart of a monitoring and early warning method based on a second usage index according to this embodiment;
fig. 4 is a schematic diagram of monitoring and early warning provided in an embodiment of the present application;
fig. 5 is a schematic flowchart of a historical data monitoring method according to an embodiment of the present disclosure;
fig. 6 is a schematic flowchart of a monitoring method based on monitoring packets according to an embodiment of the present application;
FIG. 7 is a schematic view of an apparatus for monitoring clinical application of antibacterial agents provided in an embodiment of the present application;
fig. 8 is a schematic view of an electronic device according to an embodiment of the present application.
Icon: 701-acquisition module, 702-first calculation module, 703-second calculation module, 704-early warning module, 801-processor and 802-storage medium.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are some embodiments of the present application, but not all embodiments. The components of the embodiments of the present application, generally described and illustrated in the figures herein, can be arranged and designed in a wide variety of different configurations.
Thus, the following detailed description of the embodiments of the present application, presented in the accompanying drawings, is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments obtained by a person of ordinary skill in the art based on the embodiments in the present application without making any creative effort belong to the protection scope of the present application.
It should be noted that: like reference numbers and letters refer to like items in the following figures, and thus, once an item is defined in one figure, it need not be further defined and explained in subsequent figures.
Furthermore, the appearances of the terms "first," "second," and the like, if any, are only used to distinguish one description from another and are not to be construed as indicating or implying relative importance.
It should be noted that the features of the embodiments of the present invention may be combined with each other without conflict.
Antibacterial agents are agents that inhibit or kill bacteria and are used for the prevention and treatment of bacterial infections. The indications to be strictly controlled by the use of antibacterial drugs are to select the drugs according to the conditions such as the antibacterial spectrum of antibiotics, clinical diagnosis of diseases, bacteriological examination, and the like. However, an antibacterial drug clinical application monitoring system is not established in a hospital, the hospital needs to manually complete the combing, extracting, counting and reporting of clinical drug application monitoring data, the workload is high, and errors are easy to occur; the clinical application condition of the antibacterial drugs in the hospital can not be dynamically monitored, doctors cannot see the clinical application condition of the antibacterial drugs in real time, and cannot timely send out early warning to managers.
In order to facilitate monitoring of the clinical application condition of the antibacterial drug, the application provides a method, a device and equipment for monitoring the clinical application of the antibacterial drug.
The following first explains a method for monitoring clinical application of an antibacterial agent provided by the present application by way of specific examples. Fig. 1 is a schematic flow chart of a method for monitoring clinical application of an antibacterial agent according to an embodiment of the present application, where an execution subject of the method is an electronic device, and the electronic device may be a device with a computing processing function, such as a desktop computer, a tablet computer, and the like. As shown in fig. 1, the method includes:
s101, acquiring clinical use data of the antibacterial drugs to be monitored in the preset hospital in a preset monitoring period.
In the actual monitoring, the hospital to be monitored is determined as a preset hospital according to the monitoring demand, and a preset monitoring period (for example, 1/2021/12/31/2022/2021) is determined. Acquiring clinical use data of the antibacterial drugs to be monitored in a preset hospital within a preset monitoring period.
Illustratively, the clinical usage data includes: basic information of a plurality of inpatients, antibacterial medicine order information to be monitored and an order execution list.
Basic information for hospitalized patients includes: patient ID (patient ID unique identifier), hospital admission number (unique identifier assigned to the hospital subject according to a specific coding rule), name (surnames and names registered in official registration in the public security registration department), gender (physiological sex), date of birth (the epoch date of the day of birth of the patient), date of admission (the epoch date of the patient when admission is handled), hospital admission diagnosis code (ICD-10 and ICD-11 codes determined by the treating physician when the patient is admitted), ICD (international disease classification), hospital admission diagnosis name (the diagnosis name of the patient when the patient is admitted), treating physician ID (unique identifier of the physician), hospital admission bed number (the number corresponding to the patient's hospital bed), hospital admission category (the name of the patient when the patient is admitted, the hospital admission department name), date of discharge (the epoch date of the patient when the patient is discharged), number of hospital admission (the cumulative number of the patient from admission to the patient when the patient is discharged, the number of hospital admission to the patient when the patient is discharged, the hospital admission date of the patient (the patient's hospital from the hospital yard code of the patient when the patient is discharged), and the hospital discharge number of the patient when the patient is discharged, the hospital entry date of the patient is counted as the cumulative number of hospital, the hospital discharge number of the hospital, the hospital number of the patient when the patient is counted as the hospital.
The antimicrobial medication order information to be monitored includes: patient ID (unique identification of patient identity), hospital admission number (unique identification number given to hospital patients according to a certain coding rule), hospital admission bed number (number corresponding to the bed where the patient is located), antibacterial medical order ID (unique identification of antibacterial medical order), antibacterial medical order state (to be executed/executed), antibacterial medical order setting reason (hospital feeling/normal), antibacterial medical code (unique identification of antibacterial in the hospital), antibacterial medical category (category of antibacterial, such as penicillin, cephalosporin and the like), antibacterial medical name (general name of medicine), specification (description of medicine specification, such as 0.5G), unit (description of medicine unit), such as a stent, tablet, granule, bag, bottle, pack, box, etc.), description of dosage form (e.g., injection, tablet, capsule, granule, etc.), dose (total dose of the drug used), frequency (frequency of use of the drug), route of administration (oral/intramuscular/intravenous/topical, etc.), microbiological specimen examination order (yes/no, examination order including qualified specimen bacterial culture, streptococcus pneumoniae urine antigen, legionella antigen/antibody examination, fungal smear and culture, serum fungal G experiment or GM experiment, etc.), microbiological specimen examination order ID (unique identification of associated examination order), status of microbiological specimen examination order (to be executed/executed), and/or dosage form, the attending physician ID (unique identification of the physician).
The order execution list includes: a patient ID (patient identification unique identifier), a hospital number (unique identifier given to a hospital patient according to a certain encoding rule), an order ID (order unique identifier), an execution date (the century date when the execution of the order is completed), an execution time (the completion time of the execution of the order), and an executor ID (medical staff ID for executing the order).
Specifically, after the medical advice is set, the state of the medical advice is automatically set to be executed; and after the order execution list is acquired, the order which is consistent with the order execution list in the traditional Chinese medicine order ID is executed, and the order state is updated from the to-be-executed state to the executed state. After the occurrence of the hospital-induced adverse events, the doctor selects the antibacterial drug type to order the original hospital-induced adverse events.
S102, calculating parameter values of the use indexes of the antibacterial drugs to be monitored in a preset monitoring period according to clinical use data.
The use indexes of the antibacterial drugs comprise: the usage rate of the antibacterial agent, the usage intensity of the antibacterial agent and the microorganism inspection rate before the antibacterial agent is used.
According to the clinical use data, the patients discharged in the same period in the preset monitoring period are summarized, and the patients discharged in the same period with the discharge date in the time period are defined as the patients discharged in the same period. The data collected from patients discharged at the same time includes: patient ID, hospital admission number, name, date of discharge, number of hospital admissions, antimicrobial use (Yes/No), and microbiological specimen submission (Yes/No). When the antibacterial medicine order state is executed, the antibacterial medicine use condition is recorded as 'yes'; when the state of the microbial specimen examination order is executed, the microbial specimen submission is recorded as "yes".
If the number of the patients discharged from the hospital in the same period is N, the number of the hospitalization days of the nth patient discharged from the hospital in the same period is t n . The average number of hospitalization days of the patients discharged from the hospital in the same period is
The specific calculation method is shown in the following formula (1):
in a preset monitoring period, the total using proportion of the antibacterial drugs and the total microorganism sample submission proportion can be determined according to the using conditions of the antibacterial drugs and the submission conditions of the microorganism samples of a plurality of patients discharged from the hospital at the same time. And calculating according to the total use cases of the antibacterial drugs and the number of the patients discharged from the hospital at the same period to obtain the usage rate of the antibacterial drugs, wherein the specific calculation mode is shown in the following formula (2):
wherein AUR is the usage rate of the antibacterial agent, N is the number of patients discharged from the hospital at the same period, and M is the total number of cases of using the antibacterial agent (i.e. the number of patients discharged from the hospital at the same period when the usage condition of the antibacterial agent is "YES").
Calculating the microbial delivery rate before the antibacterial agent is used according to the total number of the antibacterial agent used and the total number of the microbial sample delivery, wherein the specific calculation mode is shown in the following formula (3):
wherein MER is the delivery rate of the microorganisms before the antimicrobial drugs are used, G is the total number of instances of delivery of the microorganism samples, and M is the total number of instances of use of the antimicrobial drugs (i.e., the number of patients who are discharged from the hospital at the same time when the delivery of the microorganism samples is yes).
According to clinical use data, the use conditions of the antibacterial drugs in a preset monitoring period are summarized. The summary data includes: drug code, drug name, specification, unit, dosage form, dosage.
The antibacterial drug use strength can be calculated according to the summarized data of the use conditions of a plurality of antibacterial drugs, and the specific calculation mode is shown in the following formula (4):
wherein AUD is the antibacterial use strength, K is the antibacterial code, u k Dosage for the antimicrobial drug numbered K, DDD k The defined daily dosage is the antimicrobial drug numbered K.
Illustratively, under the drug name: examples of the penicillin sodium injection, penicillin V tablet, oxacillin sodium injection, cloxacillin capsule, cloxacillin injection, cephalexin capsule, cephalexin tablet, and cefozopran sodium injection include DDD. The medicines with the same medicine name comprise different specifications, and the corresponding DDD values of the medicines with different specifications in the same medicine name are the same. The name, specification, unit and dosage form of the corresponding drug of the same drug code are all unique. Therefore, the corresponding DDD values of different drug codes are determined, and the method has uniqueness.
Specifically, as shown in table 1 below:
| drug coding | Name of drug | Specification of | Unit of | Dosage forms | DDD value |
| J01CE01-1 | Penicillin sodium injection | 1.6MU | Branch stand | Injection preparation | 3.6g |
| J01CE01-2 | Penicillin sodium injection | 0.8MU | Branch stand | Injection preparation | 3.6g |
| J01CE02-1 | Penicillin V tablet | 0.125g | Sheet | Tablet formulation | 2.0g |
| J01CE02-2 | Penicillin V tablet | 0.25g | Sheet | Tablet formulation | 2.0g |
| J01CF04-1 | Oxacillin sodium injection | 0.5g | Branch stand | Injection preparation | 2.0g |
| J01CF04-2 | Oxacillin sodium injection | 1.0g | Branch stand | Injection preparation | 2.0g |
| J01CF02-1 | Cloxacillin capsule | 0.125g | Granule | Capsule | 2.0g |
| J01CF02-2 | Cloxacillin capsule | 0.25g | Granule | Capsule | 2.0g |
| J01CF02-3 | Cloxacillin injection | 0.5g | Branch stand | Injection preparation | 2.0g |
| J01CF05-1 | Flucloxacillin capsule | 0.125g | Sheet | Tablet formulation | 2.0g |
| J01CF05-2 | Flucloxacillin injection | 0.5g | Branch stand | Injection preparation | 2.0g |
| J01DB01-1 | Cefalexin capsule | 0.25g | Granule | Capsule | 2.0g |
| J01DB01-2 | Cefalexin tablet | 0.25g | Sheet | Tablet formulation | 2.0g |
| J01DB04-1 | Cefazolin sodium injection | 0.5g | Branch stand | Injection preparation | 3.0g |
TABLE 1
S103, calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index.
As can be seen from the above, the usage index includes: the usage rate of the antibacterial agent, the usage intensity of the antibacterial agent and the microorganism inspection rate before the antibacterial agent is used. The corresponding antibacterial drug use rate threshold, antibacterial drug use intensity threshold and antibacterial drug pre-use microorganism delivery rate threshold are preset. Further, a monitoring index value corresponding to the antibacterial drug use rate, a monitoring index value corresponding to the antibacterial drug use strength, and a monitoring index value corresponding to the microbial inspection rate before the antibacterial drug is used can be calculated. So as to accurately obtain the monitoring index value.
And S104, performing early warning monitoring on the use indexes of the antibacterial drugs to be monitored according to the monitoring index values corresponding to the use indexes.
And taking the monitoring index value as an early warning reference, and carrying out multi-dimensional early warning monitoring on the use index of the antibacterial drug to be monitored according to the monitoring index value corresponding to the antibacterial drug use rate, the monitoring index value corresponding to the antibacterial drug use strength and the monitoring index value corresponding to the microorganism delivery rate before the antibacterial drug is used. The accurate monitoring index value is adopted to timely monitor and early warn the use condition of the antibacterial drugs, so that the hospital can manage the antibacterial drugs conveniently.
In summary, in the embodiment, clinical usage data of the antibacterial agent to be monitored in the preset monitoring period in the preset hospital is obtained; calculating the parameter value of the use index of the antibacterial drug to be monitored in a preset monitoring period according to clinical use data; calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index; and carrying out early warning monitoring on the use indexes of the antibacterial drugs to be monitored according to the monitoring index values corresponding to the use indexes. Therefore, accurate monitoring index values can be adopted in different monitoring periods, the using condition of the antibacterial drugs can be monitored and early warned in time, and the hospital can manage the antibacterial drugs conveniently.
Further, on the basis of fig. 1, calculating a monitoring index value corresponding to the usage index according to the parameter value of the usage index and the parameter threshold value corresponding to the usage index in S103 includes:
and calculating a monitoring index value corresponding to the use index according to the ratio of the parameter value of the use index to the parameter threshold value corresponding to the use index.
Specifically, a monitoring index value corresponding to the antibacterial drug utilization rate is calculated according to the ratio of the parameter value of the antibacterial drug utilization rate to the antibacterial drug utilization rate threshold value. Specifically, the calculation is as shown in the following formula (5):
wherein AUR Threshold value As a threshold for the rate of use of antibacterial drugs, A AUR The index value is a monitoring index value corresponding to the usage rate of the antibacterial drugs.
And calculating a monitoring index value corresponding to the use strength of the antibacterial drug according to the ratio of the parameter value of the use strength of the antibacterial drug to the use strength threshold value of the antibacterial drug. Specifically, the calculation is as shown in the following equation (6):
wherein AUD Threshold value For antimicrobial use intensity threshold, A AUD The index value is a monitoring index value corresponding to the use strength of the antibacterial drug.
And calculating the monitoring index value of the microbial delivery rate before the antibacterial medicament is used according to the ratio of the parameter value of the microbial delivery rate before the antibacterial medicament is used to the microbial delivery rate threshold before the antibacterial medicament is used. Specifically, the calculation is as shown in the following formula (7):
wherein, MER Threshold value The threshold value of the microbial detection rate before the use of the antibacterial drug is A MER Corresponding to the microbial detection rate before use of the antibacterial agentAnd monitoring the index value.
The monitoring index value is calculated by presetting the parameter threshold value and adopting the ratio of the parameter value to the parameter threshold value, so that the monitoring index for monitoring is more accurate.
Further, on the basis of fig. 1, the early warning monitoring of the usage index of the antibacterial agent to be monitored according to the monitoring index value corresponding to the usage index in S104 includes:
according to the early warning index range of the monitoring index value corresponding to the use index, determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period as follows: and early warning level corresponding to the early warning index range.
The early warning indexes of the use indexes are divided into at least one early warning index range in advance, the range division mode is not limited, and it needs to be stated that the more the divided early warning index ranges are, the more accurate the monitoring and early warning is.
Correspondingly, according to the monitoring index value corresponding to the antibacterial utilization rate, determining the early warning index range in which the antibacterial utilization rate is located, and determining the early warning level of the antibacterial utilization rate as the early warning level corresponding to the early warning index range.
And determining the early warning index range of the use strength of the antibacterial drug according to the monitoring index value corresponding to the use strength of the antibacterial drug, and determining the early warning level of the use strength of the antibacterial drug as the early warning level corresponding to the early warning index range.
According to the monitoring index value corresponding to the microbial submission rate before the antibacterial agent is used, determining the early warning index range in which the microbial submission rate before the antibacterial agent is used is located, and determining the early warning level of the microbial submission rate before the antibacterial agent is used as the early warning level corresponding to the early warning index range.
Therefore, the early warning levels of the antibacterial drugs in different dimensions are accurately determined by dividing the early warning index range. And show the early warning rank to help predetermine the hospital and carry out the antibiotic medicine in service behavior and carry out the early warning.
Fig. 2 is a schematic flow chart of a monitoring and early warning method based on a first usage index according to this embodiment. The usage index includes: the first usage index, for example, may be an antimicrobial usage rate and/or an antimicrobial usage intensity.
As shown in fig. 2, according to the early warning index range of the monitoring index value corresponding to the usage index, determining the early warning level of the usage index of the antibacterial agent to be monitored in the preset monitoring period as follows: the early warning level corresponding to the early warning index range comprises the following steps:
s201, if the monitoring index value corresponding to the first use index is larger than or equal to the first early warning threshold value and smaller than 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level.
The first early warning threshold value is any value which is greater than 0 and less than 1.
And if the monitoring index value corresponding to the first use index is greater than or equal to the first early warning threshold value and less than 1, determining that the parameter value of the first use index is less than the parameter threshold value. For example, in clinical treatment, to ensure that the antibacterial drug is not abused, the antibacterial drug usage rate and the antibacterial drug usage intensity are certainly as small as possible, and when the parameter value of the first usage index is smaller than the parameter threshold value, the first warning level is certainly in a lower risk range, namely, the first warning level is the low risk warning level.
S202, if the monitoring index value corresponding to the first use index is larger than or equal to 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level;
wherein the first warning level is lower than the second warning level.
And if the monitoring index value corresponding to the first use index is greater than or equal to 1, determining that the parameter value of the first use index is greater than or equal to the parameter threshold value. Illustratively, in clinical treatment, when the parameter value of the first usage index is greater than or equal to the parameter threshold value, the first usage index is already in a higher risk range, i.e. the second early warning level is a high risk early warning level.
Further, if the monitoring index value corresponding to the first use index is smaller than the first early warning threshold value, the first use index of the antibacterial drug to be monitored in the preset monitoring period is determined to be in a normal level.
In summary, in this embodiment, if the monitoring index value corresponding to the first usage index is greater than or equal to the first early warning threshold and less than 1, it is determined that the first usage index of the antibacterial agent to be monitored in the preset monitoring period is at the first early warning level; the first early warning threshold value is any value which is greater than 0 and less than 1; if the monitoring index value corresponding to the first use index is greater than or equal to 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level; wherein the first warning level is lower than the second warning level. Therefore, the early warning is more accurate by carrying out range division on the first use index.
Fig. 3 is a schematic flow chart of a monitoring and early warning method based on a second usage index according to this embodiment. The usage index includes: the second usage index, for example, is the microbial delivery rate before use of the antimicrobial agent.
As shown in fig. 3, according to the early warning index range where the monitoring index value corresponding to the usage index is located, determining that the early warning level where the usage index of the antibacterial agent to be monitored is located in the preset monitoring period is: the early warning level corresponding to the early warning index range comprises the following steps:
s301, if the monitoring index value corresponding to the second use index is larger than or equal to 1 and smaller than the second early warning threshold value, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at the first early warning level.
And the second early warning threshold value is any value greater than 1.
And if the monitoring index value corresponding to the second use index is greater than or equal to 1 and smaller than the second early warning threshold value, determining that the parameter value of the second use index is greater than or equal to the parameter threshold value. For example, in clinical treatment, in order to ensure safe use of antibacterial drugs, microbial censorship is performed before the antibacterial drugs are used. Therefore, the higher the microorganism delivery rate before the antibacterial drug is used, the better, when the parameter value of the second use index is greater than or equal to 1 and less than the second early warning threshold value, the lower risk range is determined, that is, the first early warning level is the low risk early warning level.
S302, if the monitoring index value corresponding to the second use index is smaller than 1, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level.
Wherein the first warning level is lower than the second warning level.
And if the monitoring index value corresponding to the second use index is smaller than 1, determining that the parameter value of the second use index is smaller than the parameter threshold value. Illustratively, in the clinical treatment, when the parameter value of the second usage index is smaller than the parameter threshold value, the second early warning level is already in a higher risk range, namely the second early warning level is a high risk early warning level.
Further, if the monitoring index value corresponding to the second use index is greater than or equal to the second early warning threshold value, it is determined that the second use index of the antibacterial drug to be monitored in the preset monitoring period is in a normal level.
In summary, in this embodiment, if the monitoring index value corresponding to the second usage index is greater than or equal to 1 and smaller than the second early warning threshold, it is determined that the second usage index of the antibacterial agent to be monitored in the preset monitoring period is at the first early warning level; the second early warning threshold value is any value greater than 1; if the monitoring index value corresponding to the second use index is smaller than 1, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level; wherein the first warning level is lower than the second warning level. Therefore, the range division is carried out on the second use index, so that the early warning is more accurate.
Further, on the basis of the embodiments shown in fig. 2 and fig. 3, the embodiment of the present application further provides a schematic diagram of monitoring and early warning. Fig. 4 is a schematic diagram of monitoring and early warning provided in an embodiment of the present application. As shown in fig. 4, the first warning threshold of the first usage index is A1, and the second warning threshold of the second usage index is A2. Exemplarily, a shaded part corresponding to the first usage index in the graph is a monitoring index value corresponding to the first usage index, that is, the first usage index is at a first early warning level; the shaded part corresponding to the second use index in the graph is a monitoring index value corresponding to the second use index, namely the second use index is at the first early warning level. When the monitoring index value is actually displayed, the monitoring index values at different levels can display different colors, and specific monitoring index values are displayed, so that a user can conveniently check the monitoring index values.
Fig. 5 is a schematic flowchart of a historical data monitoring method according to an embodiment of the present disclosure. As shown in fig. 5, the calculating of the monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index in S103 includes:
s401, calculating the variable quantity of the use parameter corresponding to the use index according to the parameter value of the use index and the historical parameter value corresponding to the use index in the historical monitoring period before the preset monitoring period.
The parameter value of the current use index can be compared with any historical parameter value corresponding to the use index so as to monitor the current use condition and the historical use condition of the antibacterial drug. Illustratively, the monitoring period may be one day, one month, one year, corresponding to one day, one month, one year of historical comparative monitoring.
Specifically, the variation of the usage parameter of the usage rate of the antibacterial drug is calculated as shown in the following formula (8):
ΔAUR＝AUR T -AUR T-1 (8)
wherein, delta AUR is the variable quantity of the usage parameters of the usage rate of the antibacterial agent, AUR T AUR as a parameter value of the usage rate of an antibacterial drug T-1 Historical parameter values for antimicrobial usage rates.
Specifically, the variation of the use parameter of the use intensity of the antibacterial agent is calculated as shown in the following formula (9):
ΔAUD＝AUD T -AUD T-1 (9)
wherein, the delta AUD is the variation of the use parameter of the use strength of the antibacterial drug, and AUD T Parameter value for the intensity of use of the antibacterial agent, AUD T-1 Historical parameter values for the intensity of antimicrobial use.
Specifically, the variation of the use parameter of the use intensity of the antibacterial agent is calculated as shown in the following formula (10):
ΔMER＝MER T -MER T-1 (10)
wherein, the delta MER is the variation of the use parameter of the microorganism inspection rate before the use of the antibacterial drug, and the MER T The MER is the parameter value of the microorganism inspection rate before the use of the antibacterial drug T-1 Historical values for the microbial delivery rate prior to use of the antimicrobial.
S402, calculating a monitoring index value corresponding to the use index according to the ratio of the variable quantity of the use parameter corresponding to the use index to the parameter value of the use index.
Specifically, the calculation manner of the monitoring index value of the usage rate of the antibacterial drug is shown in the following formula (11):
wherein, ROC AUR Is a monitoring index value of the usage rate of the antibacterial drugs.
Specifically, the calculation mode of the monitoring index value of the use intensity of the antibacterial agent is shown in the following formula (12):
wherein, ROC AUD Is a monitoring index value of the use strength of the antibacterial drug.
Specifically, the calculation mode of the monitoring index value of the microbial detection rate before the antibacterial agent is used is shown in the following formula (13):
wherein, ROC MER Is a monitoring index value of the microorganism inspection rate before the antibacterial drug is used.
In summary, in this embodiment, the usage parameter variation corresponding to the usage index is calculated according to the parameter value of the usage index and the historical parameter value corresponding to the usage index in the historical monitoring period before the preset monitoring period; and calculating a monitoring index value corresponding to the use index according to the ratio of the variable quantity of the use parameter corresponding to the use index to the parameter value of the use index. Thus, by adopting historical parameters, multi-dimensional monitoring is carried out.
Fig. 6 is a schematic flowchart of a monitoring method based on monitoring packets according to an embodiment of the present application. If the clinical usage data includes: clinical usage data of at least one monitoring group. As shown in fig. 6, the step S102 of calculating a parameter value of the usage index of the antibacterial agent to be monitored in the preset monitoring period according to the clinical usage data includes:
and S501, calculating a parameter value of the use index in each monitoring group according to the clinical use data of each monitoring group.
Clinical usage data for each monitoring group is acquired from the clinical usage data. According to the clinical use data of each monitoring group, the antibacterial drug use rate, the antibacterial drug use strength and the microbial delivery rate before the antibacterial drug use in each monitoring group can be calculated.
The specific calculation method is shown in the above equations (1), (2), (3), and (4), and will not be described herein again.
Further, in S103, calculating a monitoring index value corresponding to the usage index according to the parameter value of the usage index and the parameter threshold corresponding to the usage index includes:
s502, calculating the monitoring index value of the use index in each monitoring group according to the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group.
After the monitoring grouping is performed, in order to facilitate the monitoring of each monitoring grouping, a parameter threshold corresponding to each monitoring grouping may be preset according to the actual situation of each monitoring grouping. And calculating the monitoring index value of the use index in each monitoring group based on the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group. So that the monitoring index value is more accurate.
To sum up, in the present embodiment, a parameter value of the usage index within each monitoring group is calculated according to the clinical usage data of each monitoring group; and calculating the monitoring index value of the use index in each monitoring group according to the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group. Thereby, to make the monitoring index value more accurate.
Further, the at least one monitoring packet may include: at least one monitoring group of a drug code group, a drug category group, a department group, a doctor group, an administration route group, and a hospital occurrence group.
Illustratively, the medicine code groups can further include sub-groups corresponding to each medicine code, the medicine category groups can further include sub-groups corresponding to each medicine category, the doctor groups can further include sub-groups corresponding to each doctor, and the medication route groups can further include sub-groups corresponding to different medication routes. For each group and each subgroup, a corresponding parameter threshold value needs to be preset according to actual conditions so as to facilitate monitoring. It should be noted that the above monitoring packets are only examples, and the specific packet types can be set according to actual needs, and are not limited to the above categories.
Specifically, the drug code packet may include: number J01CE01-1, corresponding to antibacterial drug usage rate number J01CE01-1, and antibacterial drug usage rate threshold value number J01CE01-1
The threshold may be 40%; corresponding to the use intensity of the antibacterial agent numbered J01CE01-1, and the use intensity threshold of the antibacterial agent numbered J01CE01-1
The threshold may be 30; corresponding to the microbial detection rate before the antibacterial agent with the number J01CE01-1 is used and the microbial detection rate threshold value before the antibacterial agent with the number J01CE01-1 is used
The threshold may be 25.
Specifically, the drug category grouping may include:penicillins, corresponding antibacterial drug use rates of penicillins, and antibacterial drug use rate threshold of penicillins
The threshold may be 40%; the use strength of the antibacterial drugs corresponding to the penicillins and the use strength threshold of the antibacterial drugs corresponding to the penicillins
The threshold may be 20; microbial detection rate before use of antibacterial drugs corresponding to penicillins and microbial detection rate threshold before use of antibacterial drugs corresponding to penicillins
The threshold may be 22.
Specifically, the department grouping may include: neurosurgery corresponding to neurosurgical antibacterial drug usage, and neurosurgical antibacterial drug usage threshold
The threshold may be 70%; corresponding to the use intensity of the antibacterial agent in neurosurgery and the use intensity threshold value of the antibacterial agent in neurosurgery
The threshold may be 60; corresponding to the microbial delivery rate before the antibacterial agent in neurosurgery is used and the microbial delivery rate threshold before the antibacterial agent in neurosurgery is used
The threshold may be 12.
Specifically, the physician grouping may include: a primary doctor ID, an antibacterial usage rate corresponding to the primary doctor ID, and an antibacterial usage rate threshold of the primary doctor ID
The threshold valueMay be 70%; the using intensity of the antibacterial agent corresponding to a certain ID of the treating doctor and the threshold of the using intensity of the antibacterial agent corresponding to the ID of the treating doctor
The threshold may be 60; the microbial delivery rate of the antibacterial agent corresponding to the ID of a doctor before use and the microbial delivery rate threshold of the antibacterial agent corresponding to the ID of the doctor before use
The threshold may be 12.
Specifically, the route group may include: oral administration corresponding to oral administration antibacterial drug usage rate, and oral administration antibacterial drug usage rate threshold
The threshold may be 40%; corresponding to the use intensity of the oral antibacterial drugs and the use intensity threshold of the oral antibacterial drugs
The threshold may be 20; corresponding to the microbial delivery rate before the oral antibacterial medicament is used and the microbial delivery rate threshold before the oral antibacterial medicament is used
The threshold may be 20.
Specifically, the nosocomial occurrence grouping may include: rate of use of antibacterial agent for occurrence of hospitalization, and threshold value of rate of use of antibacterial agent for occurrence of hospitalization
The threshold may be 10%; the use intensity of the antibacterial agent corresponding to the occurrence of nosocomial infection, and the threshold of the use intensity of the antibacterial agent corresponding to the occurrence of nosocomial infection
The threshold may be 20(ii) a Microbial detection rate before use of antibacterial agent corresponding to nosocomial infection, and microbial detection rate threshold before use of antibacterial agent corresponding to nosocomial infection
The threshold may be 10.
Furthermore, the plurality of sub-packets can be sorted according to the parameter values of the plurality of sub-packets in each monitoring packet, and the sorting result is displayed. Illustratively, the route of medication ranked 5 for antibacterial usage is: oral administration, intravenous drip, intravenous injection, intramuscular injection, topical application; the classes of drugs ranked 5 top in the antibacterial use strength are: cephalosporins, quinolones, beta-lactamase inhibitors, penicillins, nitroimidazoles; the department with the microorganism inspection rate ranking 5 before the use of the total antibacterial drugs is as follows: intensive care unit, department of respiratory medicine, newborn paediatrics, department of neurology, hematology.
For example, the ratio of the antimicrobial usage rate, the antimicrobial usage intensity, the microbial detection rate before the antimicrobial usage to the total antimicrobial usage rate, the total antimicrobial usage intensity, and the microbial detection rate before the total antimicrobial usage, which correspond to a doctor, is calculated as shown in the following formulas (11), (12), and (13):
wherein, AURR Doctor The ratio of the antibacterial drug utilization rate to the total antibacterial drug utilization rate, AUDR, corresponding to a doctor Doctor The ratio of the antibacterial drug use strength to the total antibacterial drug use strength, MERR, corresponding to a doctor Doctor The ratio of the microorganism delivery rate before the use of the antibacterial drug corresponding to a doctor to the total microorganism delivery rate before the use of the antibacterial drug.
Furthermore, the user can inquire the monitoring data according to the conditions of the preset monitoring period, the monitoring grouping and the like. A plurality of preset monitoring periods can be set, and monitoring data and early warning conditions of the plurality of preset monitoring periods are acquired and displayed simultaneously. And a preset pushing mechanism can be set, so that the monitoring data and the early warning condition corresponding to a doctor can be pushed and displayed in real time.
The following describes a device, a storage medium, and the like for performing clinical application monitoring of an antibacterial agent provided by the present application, and specific implementation processes and technical effects thereof are referred to above and will not be described again below.
Fig. 7 is a schematic view of an antibacterial clinical application monitoring device provided in an embodiment of the present application, and as shown in fig. 7, the device includes:
an obtaining module 701, configured to obtain clinical usage data of an antibacterial agent to be monitored in a preset monitoring period in a preset hospital.
A first calculating module 702, configured to calculate, according to the clinical usage data, a parameter value of a usage index of the antibacterial agent to be monitored in a preset monitoring period.
The second calculating module 703 is configured to calculate a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold corresponding to the use index.
And the early warning module 704 is used for performing early warning monitoring on the use index of the antibacterial drug to be monitored according to the monitoring index value corresponding to the use index.
Further, the second calculating module 703 is specifically configured to calculate a monitoring index value corresponding to the use index according to a ratio between the parameter value of the use index and the parameter threshold value corresponding to the use index.
Further, the second calculating module 703 is specifically configured to determine, according to the early warning index range where the monitoring index value corresponding to the usage index is located, that the usage index of the antibacterial agent to be monitored in the preset monitoring period is located at an early warning level: and early warning levels corresponding to the early warning index ranges.
Further, the second calculating module 703 is specifically configured to use the index, and includes: a first usage index; according to the early warning index range of the monitoring index value corresponding to the use index, determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period as follows: the early warning level corresponding to the early warning index range comprises the following steps: if the monitoring index value corresponding to the first use index is greater than or equal to the first early warning threshold value and less than 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level; the first early warning threshold value is any value which is greater than 0 and less than 1; if the monitoring index value corresponding to the first use index is greater than or equal to 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level; wherein the first warning level is lower than the second warning level.
Further, the second calculating module 703 is specifically configured to use the index, and includes: a second usage index; according to the early warning index range of the monitoring index value corresponding to the use index, determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period as follows: the early warning level corresponding to the early warning index range comprises the following steps: if the monitoring index value corresponding to the second use index is greater than or equal to 1 and smaller than a second early warning threshold value, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at the first early warning level; the second early warning threshold value is any value larger than 1; if the monitoring index value corresponding to the second use index is smaller than 1, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level; wherein the first warning level is lower than the second warning level.
Further, the second calculating module 703 is specifically configured to calculate a variation of the usage parameter corresponding to the usage index according to the parameter value of the usage index and a historical parameter value corresponding to the usage index in a historical monitoring period before a preset monitoring period; and calculating a monitoring index value corresponding to the use index according to the ratio of the variable quantity of the use parameter corresponding to the use index to the parameter value of the use index.
Further, the first calculation module 702 is specifically configured to, if the clinical usage data includes: clinical usage data of at least one monitoring group; according to clinical use data, calculating the parameter value of the use index of the antibacterial drug to be monitored in a preset monitoring period, wherein the parameter value comprises the following steps: a parameter value of the usage index within each monitoring group is calculated based on the clinical usage data for each monitoring group.
Further, the second calculating module 703 is specifically configured to calculate a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold corresponding to the use index, and includes: and calculating the monitoring index value of the use index in each monitoring group according to the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group.
Further, the first calculating module 702, specifically for the at least one monitoring packet, includes: at least one monitoring group of a drug code group, a drug category group, a department group, a doctor group, an administration route group, and a hospital occurrence group.
Fig. 8 is a schematic view of an electronic device according to an embodiment of the present application, where the electronic device may be a device with a computing processing function. As shown in fig. 8:
the electronic device includes: a processor 801, a storage medium 802. The processor 801 and the storage medium 802 are connected by a bus.
The storage medium 802 is used for storing a program, and the processor 801 calls the program stored in the storage medium 802 to execute the above-described method embodiments. The specific implementation and technical effects are similar, and are not described herein again.
Optionally, the invention also provides a program product, for example a computer-readable storage medium, comprising a program which, when being executed by a processor, is adapted to carry out the above-mentioned method embodiments.
In the embodiments provided in the present invention, it should be understood that the disclosed apparatus and method may be implemented in other ways. For example, the above-described apparatus embodiments are merely illustrative, and for example, the division of the units is only one logical division, and other divisions may be realized in practice, for example, a plurality of units or components may be combined or integrated into another system, or some features may be omitted, or not executed. In addition, the shown or discussed mutual coupling or direct coupling or communication connection may be an indirect coupling or communication connection through some interfaces, devices or units, and may be in an electrical, mechanical or other form.
The units described as separate parts may or may not be physically separate, and parts displayed as units may or may not be physical units, may be located in one position, or may be distributed on multiple network units. Some or all of the units can be selected according to actual needs to achieve the purpose of the solution of the embodiment.
In addition, functional units in the embodiments of the present invention may be integrated into one processing unit, or each unit may exist alone physically, or two or more units are integrated into one unit. The integrated unit can be realized in a form of hardware, or in a form of hardware plus a software functional unit.
The integrated unit implemented in the form of a software functional unit may be stored in a computer-readable storage medium. The software functional unit is stored in a storage medium and includes several instructions to enable a computer device (which may be a personal computer, a server, or a network device) or a processor (processor) to execute some steps of the methods according to the embodiments of the present invention. And the aforementioned storage medium includes: a U-disk, a portable hard disk, a Read-Only Memory (ROM), a Random Access Memory (RAM), a magnetic disk or an optical disk, and other media capable of storing program codes.
Claims (10)
1. A method for monitoring clinical application of an antibacterial agent, the method comprising:
acquiring clinical use data of an antibacterial drug to be monitored in a preset hospital within a preset monitoring period;
calculating the parameter value of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical use data;
calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and a parameter threshold value corresponding to the use index;
and carrying out early warning monitoring on the use index of the antibacterial drug to be monitored according to the monitoring index value corresponding to the use index.
2. The method of claim 1, wherein the calculating a monitoring index value corresponding to the usage index according to the parameter value of the usage index and the parameter threshold value corresponding to the usage index comprises:
and calculating a monitoring index value corresponding to the use index according to the ratio of the parameter value of the use index to the parameter threshold value corresponding to the use index.
3. The method according to claim 2, wherein the performing the early warning monitoring of the usage index on the antibacterial drug to be monitored according to the monitoring index value corresponding to the usage index comprises:
determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: and the early warning level corresponds to the early warning index range.
4. The method of claim 3, wherein the usage index comprises: a first usage index;
and determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: the early warning level corresponding to the early warning index range comprises the following steps:
if the monitoring index value corresponding to the first use index is greater than or equal to a first early warning threshold value and less than 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level; the first early warning threshold value is any value which is greater than 0 and less than 1;
if the monitoring index value corresponding to the first use index is greater than or equal to 1, determining that the first use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level;
wherein the first warning level is lower than the second warning level.
5. The method of claim 3, wherein the usage index comprises: a second usage index;
and determining the early warning level of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the early warning index range of the monitoring index value corresponding to the use index as follows: the early warning level corresponding to the early warning index range comprises the following steps:
if the monitoring index value corresponding to the second use index is greater than or equal to 1 and smaller than a second early warning threshold value, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a first early warning level; the second early warning threshold value is any value greater than 1;
if the monitoring index value corresponding to the second use index is smaller than 1, determining that the second use index of the antibacterial drug to be monitored in the preset monitoring period is at a second early warning level;
wherein the first warning level is lower than the second warning level.
6. The method according to claim 1, wherein the calculating the monitoring index value corresponding to the usage index according to the parameter value of the usage index and the parameter threshold value corresponding to the usage index comprises:
calculating the variable quantity of the use parameter corresponding to the use index according to the parameter value of the use index and the historical parameter value corresponding to the use index in the historical monitoring period before the preset monitoring period;
and calculating a monitoring index value corresponding to the use index according to the ratio of the variable quantity of the use parameter corresponding to the use index to the parameter value of the use index.
7. The method of claim 1, wherein if the clinical usage data comprises: clinical usage data of at least one monitoring group; the calculating the parameter value of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical use data comprises the following steps:
calculating a parameter value of the usage index within each monitoring group from clinical usage data of the each monitoring group;
the calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index includes:
and calculating the monitoring index value of the use index in each monitoring group according to the parameter value of the use index in each monitoring group and the parameter threshold value corresponding to the use index in each monitoring group.
8. The method of claim 7, wherein the at least one monitoring packet comprises: at least one monitoring group of a drug code group, a drug category group, a department group, a doctor group, an administration route group, and a hospital occurrence group.
9. An antimicrobial clinical application monitoring device, the device comprising:
the acquisition module is used for acquiring clinical use data of the antibacterial drugs to be monitored in a preset hospital within a preset monitoring period;
the first calculation module is used for calculating a parameter value of the use index of the antibacterial drug to be monitored in the preset monitoring period according to the clinical use data;
the second calculation module is used for calculating a monitoring index value corresponding to the use index according to the parameter value of the use index and the parameter threshold value corresponding to the use index;
and the early warning module is used for carrying out early warning monitoring on the use index on the antibacterial drug to be monitored according to the monitoring index value corresponding to the use index.
10. An electronic device, comprising: a processor, a storage medium, the processor and the storage medium are connected through a bus communication, the storage medium stores program instructions executable by the processor, and the processor calls a program stored in the storage medium to execute the steps of the method for monitoring clinical application of antibacterial drugs according to any one of claims 1 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210806466.5A CN115171918A (en) | 2022-07-08 | 2022-07-08 | Method, device and equipment for monitoring clinical application of antibacterial drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210806466.5A CN115171918A (en) | 2022-07-08 | 2022-07-08 | Method, device and equipment for monitoring clinical application of antibacterial drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115171918A true CN115171918A (en) | 2022-10-11 |
Family
ID=83493959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210806466.5A Pending CN115171918A (en) | 2022-07-08 | 2022-07-08 | Method, device and equipment for monitoring clinical application of antibacterial drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115171918A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117809827A (en) * | 2024-03-01 | 2024-04-02 | 吉林大学 | Nursing information management system based on Internet of things |
| CN118692620A (en) * | 2024-08-22 | 2024-09-24 | 浙江大学医学院附属第二医院 | Method and system for generating clinical use course record of antibacterial drug |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111785395A (en) * | 2020-05-08 | 2020-10-16 | 四川大学华西第二医院 | Monitoring method, system, equipment and storage medium for clinical application of antibacterial drugs |
| CN114093524A (en) * | 2021-11-02 | 2022-02-25 | 深圳市儿童医院 | Children antibacterial drug use evaluation system, computer-readable storage medium and terminal |
-
2022
- 2022-07-08 CN CN202210806466.5A patent/CN115171918A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111785395A (en) * | 2020-05-08 | 2020-10-16 | 四川大学华西第二医院 | Monitoring method, system, equipment and storage medium for clinical application of antibacterial drugs |
| CN114093524A (en) * | 2021-11-02 | 2022-02-25 | 深圳市儿童医院 | Children antibacterial drug use evaluation system, computer-readable storage medium and terminal |
Non-Patent Citations (2)
| Title |
|---|
| 余长智;吐尔滚・艾萨;吴燕;徐月清;: "血清降钙素原预测慢性阻塞性肺疾病急性加重期患者院内感染的临床价值", 中华危重症医学杂志(电子版), no. 05 * |
| 俞高;: "基于数据中心的医院抗菌药物使用质控平台", 中国数字医学, no. 03, pages 1 - 3 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117809827A (en) * | 2024-03-01 | 2024-04-02 | 吉林大学 | Nursing information management system based on Internet of things |
| CN118692620A (en) * | 2024-08-22 | 2024-09-24 | 浙江大学医学院附属第二医院 | Method and system for generating clinical use course record of antibacterial drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| West et al. | ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes | |
| Daneman et al. | Antibiotic use in long-term care facilities | |
| Gonzales et al. | Excessive antibiotic use for acute respiratory infections in the United States | |
| Gonzales et al. | Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults | |
| CN105893725B (en) | A kind of Infection Prevention and control whole-process management system and method | |
| Gottesman et al. | Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting | |
| CN115171918A (en) | Method, device and equipment for monitoring clinical application of antibacterial drugs | |
| Sax et al. | Evaluation of the Emergency Severity Index in US emergency departments for the rate of mistriage. | |
| Olesen et al. | Impact of pharmaceutical care on adherence, hospitalisations and mortality in elderly patients | |
| Moehring et al. | Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy | |
| Khan et al. | Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: are there unjustified prescriptions? | |
| CN104615904A (en) | Antibacterial medicament clinical application decision support system and constructing method thereof | |
| CN107153765A (en) | The medication information processing method and device of antibacterials | |
| Scholze et al. | The reduction in antibiotic use in hospitals: a retrospective single-center study on microbiological characteristics and mortality | |
| Raka et al. | Point prevalence survey of healthcare-associated infections and antimicrobial use in Kosovo hospitals | |
| Tan et al. | A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study | |
| Arcenillas et al. | Assessment of quality indicators for appropriate antibiotic use | |
| Ray et al. | Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa | |
| Teratani et al. | Pattern of antibiotic prescriptions for outpatients with acute respiratory tract infections in Japan, 2013–15: a retrospective observational study | |
| Schneider et al. | STD care in the South African private health sector | |
| Loo et al. | Microbiology and audit of vascular access-associated bloodstream infections in multi-ethnic Asian hemodialysis patients in a tertiary hospital | |
| Thornburg et al. | Adherence to study medication and visits: data from the BABY HUG trial | |
| Zhang et al. | Paediatric osteomyelitis and septic arthritis pathogen distribution and antimicrobial resistance in a single centre: a 15-year retrospective analysis | |
| Genaneh et al. | Health care-associated infections and associated factors among adult patients admitted to intensive care units of selected public hospitals, Addis Ababa, Ethiopia | |
| Goff et al. | The impact of a multifaceted tertiary pediatric hospital’s antimicrobial stewardship service |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |